Tarsus Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
TARS
CUSIP
87650L103
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 87650L103 since 12/18/2024, largest first.

Filer % of Class Filed
Deep Track Capital, LP 13G/A
8.5% 5/15/2026
Event 3/31/2026
RTW Investments, LP 13G/A
8.1% 8/14/2025
Event 6/30/2025
BlackRock, Inc. 13G/A 7.4% 4/24/2025
Event 3/31/2025
Janus Henderson Group Ltd. 13G/A 6.5% 8/13/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (6)
Cowen Financial Products LLC 13G/A 4.9% 2/13/2025
Event 12/31/2024
Morgan Stanley 13G/A 4.7% 5/7/2025
Event 3/31/2025
Prudential Financial Inc 13G/A 4.3% 5/8/2026
Event 3/31/2026
Jennison Associates LLC 13G/A 4.0% 5/6/2026
Event 3/31/2026
Tang Capital Management LLC 13G/A
2.8% 2/17/2026
Event 12/31/2025
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 4.91 k $386 k
2026 Q2 271 50.6 M $3.08 B
2026 Q1 262 45.1 M $3.17 B
2025 Q4 253 44.1 M $3.61 B
2025 Q3 229 45.2 M $2.69 B
2025 Q2 211 48.0 M $1.95 B
2025 Q1 203 44.0 M $2.26 B
2024 Q4 207 40.3 M $2.23 B
2024 Q3 174 43.9 M $1.44 B
2024 Q2 161 42.4 M $1.15 B
2024 Q1 175 44.3 M $1.61 B
2023 Q4 126 34.8 M $705 M
2023 Q3 110 29.8 M $529 M
2023 Q2 96 21.4 M $387 M
2023 Q1 79 20.1 M $252 M
2022 Q4 73 20.9 M $306 M
2022 Q3 78 20.5 M $351 M
2022 Q2 76 20.0 M $292 M
2022 Q1 52 13.2 M $222 M
2021 Q4 45 14.4 M $323 M
2021 Q3 45 12.9 M $277 M
2021 Q2 46 14.4 M $416 M
2021 Q1 43 14.1 M $451 M
2020 Q4 41 12.8 M $524 M